Deep WGS of ctDNA characterized genomic alterations in aggressive prostate cancer, aligning with findings from tumor-based genetic studies: TP53 (73% of patients), PTEN (48% of patients), RB1 (18% of patients), ETS fusion (49% of patients), and DNA repair defects (27% of patients) [25]. The gene discussed is TP53; the disease is neoplasm.